MX2011008448A - Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia. - Google Patents

Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.

Info

Publication number
MX2011008448A
MX2011008448A MX2011008448A MX2011008448A MX2011008448A MX 2011008448 A MX2011008448 A MX 2011008448A MX 2011008448 A MX2011008448 A MX 2011008448A MX 2011008448 A MX2011008448 A MX 2011008448A MX 2011008448 A MX2011008448 A MX 2011008448A
Authority
MX
Mexico
Prior art keywords
eicosapentaenoic acid
ethyl ester
acid ethyl
treating hypertriglyceridemia
treating
Prior art date
Application number
MX2011008448A
Other languages
English (en)
Inventor
Mehar Manku
Ian Osterloh
Pierre Wicker
Rene Braeckman
Paresh Soni
Original Assignee
Amarin Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011008448(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amarin Pharma Inc filed Critical Amarin Pharma Inc
Publication of MX2011008448A publication Critical patent/MX2011008448A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass

Abstract

En varias modalidades, la presente invención proporciona métodos para el tratamiento y/o prevención de enfermedades relacionadas cardiovasculares y, en particular, un método de terapia de lípidos en sangre que comprende administrar a un sujeto, con la necesidad de esto, una composición farmacéutica que comprende ácido eicosapentaenoico o un derivado del mismo.
MX2011008448A 2009-02-10 2010-02-09 Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia. MX2011008448A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15129109P 2009-02-10 2009-02-10
US17375509P 2009-04-29 2009-04-29
PCT/US2010/023638 WO2010093634A1 (en) 2009-02-10 2010-02-09 Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia

Publications (1)

Publication Number Publication Date
MX2011008448A true MX2011008448A (es) 2012-02-28

Family

ID=42102041

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008448A MX2011008448A (es) 2009-02-10 2010-02-09 Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.

Country Status (24)

Country Link
US (29) US8293727B2 (es)
EP (5) EP3037089B1 (es)
KR (2) KR20140007973A (es)
AU (1) AU2010213899B2 (es)
BR (1) BRPI1007518A2 (es)
CA (3) CA2751576C (es)
CY (2) CY1122628T1 (es)
DK (3) DK2596786T3 (es)
ES (3) ES2426132T3 (es)
HK (2) HK1165698A1 (es)
HR (3) HRP20130811T1 (es)
HU (1) HUE048299T2 (es)
LT (2) LT3037089T (es)
MX (1) MX2011008448A (es)
NZ (1) NZ594395A (es)
PH (1) PH12015500407A1 (es)
PL (3) PL2596786T3 (es)
PT (3) PT2596786T (es)
RU (2) RU2505292C2 (es)
SG (3) SG10201400685SA (es)
SI (3) SI2395991T1 (es)
SM (1) SMT201300095B (es)
WO (1) WO2010093634A1 (es)
ZA (1) ZA201105612B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP5924834B2 (ja) 2008-09-02 2016-05-25 アマリン ファーマシューティカルズ アイルランド リミテッド エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
HUE034551T2 (en) 2009-01-12 2018-02-28 Biokier Inc Preparation and method of treating diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
LT3037089T (lt) 2009-02-10 2020-01-10 Amarin Pharmaceuticals Ireland Limited Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20120016677A (ko) 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2010298303A1 (en) 2009-09-23 2012-04-12 Biokier, Inc. Composition and method for treatment of diabetes
WO2011087981A2 (en) 2010-01-15 2011-07-21 E. I. Du Pont De Nemours And Company Clinical benefits of eicosapentaenoic acid in humans
AU2011222544A1 (en) * 2010-03-04 2012-09-27 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) * 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
ES2685703T3 (es) 2012-01-06 2018-10-10 Omthera Pharmaceuticals Inc. Composiciones enriquecidas en DPA de ácidos grasos omega-3 poliinsaturados en forma de ácido libre
WO2014189386A2 (en) * 2012-02-14 2014-11-27 Photonz Corporation Method for supervising consumption of a medical food for prevention and/or management of a disease or condition
TW201347754A (zh) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc 史他汀及ω－３脂肪酸之組合物
KR102125034B1 (ko) * 2012-05-15 2020-06-19 모치다 세이야쿠 가부시키가이샤 고혈중 고감도 c반응성 단백질 환자의 심혈관 질병 1차 예방제
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects
US20150157593A1 (en) * 2012-06-29 2015-06-11 Amarin Pharmaceuticals Ireland Limited Methods of reducing ldl-p
US20140005265A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating hypertriglyceridemia
MX2015000138A (es) 2012-06-29 2015-09-07 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
KR102103426B1 (ko) * 2012-09-28 2020-04-22 모치다 세이야쿠 가부시키가이샤 당뇨병 신규 발병 저감용 조성물
WO2014074552A2 (en) * 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US20140213648A1 (en) * 2012-12-31 2014-07-31 Amarin Pharmaceuticals Ireland Limited Methods of increasing epa blood levels
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140221452A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
US20140221358A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
KR102039522B1 (ko) * 2013-06-03 2019-11-26 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 근거리 무선 통신(ｎｆｃ)을 이용한 ｎｆｃ 태그의 기록방법 및 장치
US20140357717A1 (en) * 2013-06-04 2014-12-04 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6804823B2 (ja) * 2013-10-14 2020-12-23 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ Ａｒｉｚｏｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 白金錯体およびデバイス
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10547995B2 (en) * 2015-04-30 2020-01-28 Lg Electronics Inc. Method and device for transmitting/receiving data using Bluetooth mesh network
US10183044B2 (en) 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
JP7020756B2 (ja) 2018-09-24 2022-02-16 アマリン ファーマシューティカルズ アイルランド リミテッド 対象の心血管イベントのリスクを低減する方法

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377526A (en) * 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS6135356A (ja) * 1984-07-27 1986-02-19 Nippon Oil & Fats Co Ltd 血液脂質脂肪酸の分析方法
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
US4843095A (en) 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
CA1338683C (en) * 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions
GB2223943A (en) 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2839276B2 (ja) * 1989-01-23 1998-12-16 日本分光工業株式会社 超臨界流体抽出・分離方法及び装置
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
CA2043615C (en) 1990-06-04 2001-08-14 Kazuhiko Hata Method of producing eicosapentaenoic acid or the ester derivative thereof
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
JP3103588B2 (ja) 1990-11-16 2000-10-30 持田製薬株式会社 リポプロテイン（ａ）低下剤
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
US5215630A (en) * 1991-06-04 1993-06-01 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
AU2384292A (en) * 1991-07-30 1993-03-02 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
DE4133694C2 (de) * 1991-10-11 1993-10-07 Fresenius Ag Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) * 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
US5888541A (en) * 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) * 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
GB9300125D0 (en) 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
AU7053494A (en) 1993-06-04 1995-01-03 Martek Biosciences Corporation Method of treating coronary vascular disease using docosahexaenoic acid
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
AU2738497A (en) 1996-04-24 1997-11-12 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
TW425285B (en) 1996-06-10 2001-03-11 Viva America Marketing Inc Fish oil and garlic nutritive supplement
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
CN1109543C (zh) 1996-10-11 2003-05-28 斯卡里斯塔有限公司 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
KR100569319B1 (ko) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US20020055529A1 (en) 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
EP1072198B1 (de) * 1999-07-28 2008-05-14 SWISS CAPS Rechte und Lizenzen AG Präparat zur Verwendung als Medikament und/oder Nahrungsmittelergänzung
EP1211955A1 (en) * 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
HUP0303083A3 (en) 2000-08-15 2005-05-30 Pfizer Prod Inc Pharmaceutical compositions containing therapeutic combination of a cetp inhibitor and atorvastatin and their use
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
GB0111282D0 (en) 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
KR20040004652A (ko) * 2001-05-30 2004-01-13 랙스데일 리미티드 조효소 ｑ 및 에이코사펜타에노산（ｅｐａ）
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
HUP0200686A2 (hu) 2002-02-22 2003-09-29 EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
US20030166614A1 (en) * 2002-03-01 2003-09-04 Harrison Stanley F. Method for reducing cholesterol and triglycerides
CA2390820A1 (en) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
AU2003257550A1 (en) * 2002-08-20 2004-03-11 Nikken Chemicals Co., Ltd. Soft capsule preparation
KR101045035B1 (ko) * 2002-11-22 2011-06-30 니폰스이산가부시키가이샤 산화 안정성이 향상된 이중결합을 가진 유기물을 함유하는조성물
GB0228079D0 (en) 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
EP1603551A2 (en) 2003-03-05 2005-12-14 Solvay Pharmaceuticals GmbH Use of omega-3-fatty acids in the treatment of diabetic patients
US20060159746A1 (en) 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
ITMI20032247A1 (it) 2003-11-19 2005-05-20 Tiberio Bruzzese Interazione di derivati polari di composti insaturi con substrati inorganici
EP1711173A2 (en) * 2003-12-31 2006-10-18 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US20050272095A1 (en) * 2004-05-19 2005-12-08 Ppd Biomarker Discovery Sciences, Llc Methods of identifying biomarkers
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
ITRM20040395A1 (it) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
EP1790338A4 (en) 2004-09-13 2007-12-12 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR KERATOCONJUNTIVA DISEASES
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
WO2006035417A2 (en) 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
WO2006085144A2 (en) 2004-10-15 2006-08-17 Photonz Corporation Limited Compositions containing high omega-3 and low saturated fatty acid levels
FR2878747B1 (fr) 2004-12-03 2007-03-30 Pierre Fabre Medicament Sa Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
US20070191467A1 (en) * 2004-12-06 2007-08-16 Reliant Pharmaceutical, Inc. Statin and omega-3 fatty acids for lipid therapy
KR101356335B1 (ko) * 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
EP1861087A4 (en) 2005-03-08 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
EP1790339B1 (en) * 2005-07-08 2014-06-04 Mochida Pharmaceutical Co., Ltd. Composition for prevention of occurrence of cardiovascular event
RU2290185C1 (ru) * 2005-07-26 2006-12-27 Дмитрий Николаевич Мясников Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
WO2007016256A2 (en) 2005-07-28 2007-02-08 Reliant Pharmaceuticals, Inc. Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
ITMI20051560A1 (it) 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
WO2007051065A2 (en) 2005-10-28 2007-05-03 Numerate, Inc. Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
EP1946755B1 (en) 2005-11-11 2017-03-15 Mochida Pharmaceutical Co., Ltd. Jelly composition
ES2511772T3 (es) * 2005-12-20 2014-10-23 Cenestra, Llc Formulaciones de ácidos grasos omega-3
PT1800675E (pt) 2005-12-23 2011-08-30 Nutricia Nv COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA
WO2007091338A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 脳卒中再発予防用組成物
WO2007128801A1 (en) 2006-05-08 2007-11-15 Novartis Ag Combination of organic compounds
ES2500063T3 (es) 2006-05-31 2014-09-29 Mochida Pharmaceutical Co., Ltd. Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple
AU2007270135B9 (en) 2006-07-05 2013-06-27 Fermentalg Production of ultrapure EPA and polar lipids from largely heterotrophic culture
WO2008012329A2 (en) * 2006-07-28 2008-01-31 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
EA018734B1 (ru) 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
US20080306154A1 (en) 2006-11-03 2008-12-11 My Svensson Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
US20080125490A1 (en) * 2006-11-03 2008-05-29 My Svensson Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
WO2008088030A1 (ja) 2007-01-17 2008-07-24 Mochida Pharmaceutical Co., Ltd. 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
WO2008106787A1 (en) 2007-03-06 2008-09-12 Bioriginal Food & Science Corporation Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
CN102552213A (zh) 2007-06-29 2012-07-11 武田药品工业株式会社 无缝胶囊
US20090182049A1 (en) 2008-01-16 2009-07-16 Joar Arild Opheim Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
US20110118350A1 (en) 2008-05-20 2011-05-19 Mochida Pharmaceutical Co., Ltd. Composition for preventing cardiovascular event in high-risk patient
JP5924834B2 (ja) 2008-09-02 2016-05-25 アマリン ファーマシューティカルズ アイルランド リミテッド エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
LT3037089T (lt) 2009-02-10 2020-01-10 Amarin Pharmaceuticals Ireland Limited Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
US20120100208A1 (en) 2009-04-29 2012-04-26 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
KR20120016677A (ko) * 2009-06-15 2012-02-24 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
EA025649B1 (ru) 2010-11-04 2017-01-30 Ф.Хоффманн-Ля Рош Аг Таблетка, содержащая s-[2-([[1-(2-этилбутил)циклогексил]карбонил]амино)фенил]-2-метилпропантиоат и кроскарамеллозу натрия
US20140004183A1 (en) * 2012-06-29 2014-01-02 Amarin Pharmaceuticals Ireland Limited Methods for treating cardiovascular disease in statin-tolerant subjects

Also Published As

Publication number Publication date
PH12015500407B1 (en) 2015-09-21
US20130004567A1 (en) 2013-01-03
EP3037089B1 (en) 2019-11-27
LT2596786T (lt) 2020-01-10
PT2596786T (pt) 2020-03-04
US20120237594A1 (en) 2012-09-20
US8318715B2 (en) 2012-11-27
PL2596786T3 (pl) 2020-06-01
US8415335B2 (en) 2013-04-09
LT3037089T (lt) 2020-01-10
HRP20200068T1 (hr) 2020-04-03
US20120108659A1 (en) 2012-05-03
SI2395991T1 (sl) 2013-12-31
CY1122628T1 (el) 2021-03-12
US8377920B2 (en) 2013-02-19
KR20140007973A (ko) 2014-01-20
HRP20130811T1 (en) 2013-09-30
RU2686315C2 (ru) 2019-04-25
RU2505292C2 (ru) 2014-01-27
US20170119722A1 (en) 2017-05-04
US8399446B2 (en) 2013-03-19
KR101383006B1 (ko) 2014-04-08
CY1122629T1 (el) 2021-03-12
SI3037089T1 (sl) 2020-03-31
SG10201400685SA (en) 2015-01-29
EP2395991B1 (en) 2013-05-29
EP2596786A1 (en) 2013-05-29
US20130096197A1 (en) 2013-04-18
ES2769926T3 (es) 2020-06-29
DK2596786T3 (da) 2020-02-24
US8367652B2 (en) 2013-02-05
HK1226307A1 (zh) 2017-09-29
US20180185320A1 (en) 2018-07-05
US8518929B2 (en) 2013-08-27
PH12015500407A1 (en) 2015-09-21
SG10201610916SA (en) 2017-02-27
US20130005809A1 (en) 2013-01-03
US20130331447A1 (en) 2013-12-12
US8324195B2 (en) 2012-12-04
AU2010213899A1 (en) 2011-08-25
US20130004566A1 (en) 2013-01-03
KR20110110321A (ko) 2011-10-06
CA3008079A1 (en) 2010-08-19
US8426399B2 (en) 2013-04-23
ZA201105612B (en) 2012-10-31
HUE048299T2 (hu) 2020-07-28
CA3008079C (en) 2020-09-22
HRP20200065T1 (hr) 2020-04-03
CA2751576A1 (en) 2010-08-19
US20190038590A1 (en) 2019-02-07
NZ594395A (en) 2014-01-31
RU2013154780A (ru) 2015-06-20
WO2010093634A1 (en) 2010-08-19
US20110288171A1 (en) 2011-11-24
US20120157530A1 (en) 2012-06-21
CA2751576C (en) 2018-07-03
US20130164375A1 (en) 2013-06-27
US8524698B2 (en) 2013-09-03
PT2395991E (pt) 2013-09-03
ES2426132T3 (es) 2013-10-21
EP3865128A1 (en) 2021-08-18
US8357677B1 (en) 2013-01-22
HK1165698A1 (en) 2012-10-12
DK2395991T3 (da) 2013-09-02
US20120093924A1 (en) 2012-04-19
RU2019111131A (ru) 2020-10-15
SI2596786T1 (sl) 2020-03-31
US20120039997A1 (en) 2012-02-16
EP3616694A1 (en) 2020-03-04
CA3089847A1 (en) 2010-08-19
US20130171249A1 (en) 2013-07-04
ES2768091T3 (es) 2020-06-19
US20130171250A1 (en) 2013-07-04
US20120108663A1 (en) 2012-05-03
PL2395991T3 (pl) 2013-11-29
US20130017256A1 (en) 2013-01-17
DK3037089T3 (da) 2020-01-20
EP2395991A1 (en) 2011-12-21
SMT201300095B (it) 2013-11-08
PL3037089T3 (pl) 2020-06-01
US20130004568A1 (en) 2013-01-03
RU2011137415A (ru) 2013-03-20
US8440650B1 (en) 2013-05-14
US20200246300A1 (en) 2020-08-06
AU2010213899B2 (en) 2014-02-06
CA3089847C (en) 2024-04-09
US8546372B2 (en) 2013-10-01
US20100311834A1 (en) 2010-12-09
EP2596786B1 (en) 2019-11-27
BRPI1007518A2 (pt) 2018-02-20
US20210046036A1 (en) 2021-02-18
PT3037089T (pt) 2020-03-04
US20210069142A1 (en) 2021-03-11
EP3037089A1 (en) 2016-06-29
US20120108660A1 (en) 2012-05-03
US20120156285A1 (en) 2012-06-21
US20130102674A1 (en) 2013-04-25
US8314086B2 (en) 2012-11-20
US8431560B1 (en) 2013-04-30
SG173612A1 (en) 2011-09-29
US8293727B2 (en) 2012-10-23
US8293728B2 (en) 2012-10-23
US20210251941A1 (en) 2021-08-19
US20240024277A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
MX2022010507A (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
MY158504A (en) Fatty acid niacin conjugates and their uses
MY173215A (en) Acetylcysteine compositions and methods of use thereof
IN2015DN00376A (es)
EA201101111A1 (ru) Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
NZ700399A (en) Boronic acid conjugates of oligonucleotide analogues
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
MX2010008433A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2011012595A (es) Composicion farmaceutica que comprende el uso de derivados de prostaglandina para modular las funciones mediadas por claudina y el tratamiento de trastornos dermatologicos.
CY1114276T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
UA53455U (ru) Способ лечения некоторых дерматозов
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".
TH139656A (th) เอสเทอร์โพรดรักซ์-)Ester-Pro-drugs) ของ [3-(1-(1H-อิมิดาซอล-4-อิล(เอทธิล (-2-เมทธิลฟีนิล] เมทธานอลสำหรับการรักษาโรคผิวหนัง และสภาวะทางผิวหนัง

Legal Events

Date Code Title Description
FG Grant or registration